Kairos Ventures

Vivodyne is a biotechnology company that specializes in developing an advanced automated robotic system aimed at discovering innovative drugs and cellular therapies. The company has created a microfluidic bioengineering platform that focuses on single-cell 4D phenomics, allowing for a detailed exploration of biological complexities. Its technology enables the cultivation of highly realistic human tissue models for drug discovery, incorporating an integrated confocal microscope. This platform not only accelerates the drug development process but also allows researchers to formulate tunable mixtures of compounds and cell therapies. Through its unique approach, Vivodyne seeks to advance the understanding of human health and facilitate the creation of effective treatments for various diseases.

PteroDynamics is a company dedicated to enhancing transportation through sustainable autonomous vertical takeoff and landing (VTOL) aircraft. Since its inception in 2017, the company has focused on developing innovative aircraft that reduce environmental impact while improving efficiency. Its patented Transwing design features wings that fold and unfold during flight, allowing the aircraft to transition seamlessly between rotor-wing and fixed-wing modes. This technology optimizes cargo-carrying capabilities for long-range missions, making PteroDynamics' aircraft suitable for government, military, and commercial applications. By prioritizing energy efficiency and stability, PteroDynamics aims to revolutionize air mobility and facilitate the movement of people and goods across various distances.

Behavioral Signals is a technology company that specializes in analyzing human behavior through voice data. Its flagship product, AI-MC, leverages artificial intelligence to enhance customer service operations by automatically matching customers with the most suitable agents based on voice data and emotional analysis. The company employs proprietary technologies to recognize and interpret core emotions, moods, and behavioral patterns, translating these insights into key performance indicators for businesses. This capability allows clients to process data in real-time, gaining valuable emotional and demographic insights that can inform marketing strategies and improve overall call center performance. By focusing on emotion recognition and behavioral analytics, Behavioral Signals aims to help enterprises achieve greater profitability and optimize customer interactions.

TULU is a company based in Tel Aviv, Israel, that specializes in on-demand rentals of household and lifestyle products through its application. It operates as a Usage Economy platform, providing tenants in residential buildings, student housing, and offices with convenient access to a variety of brand-name appliances, grocery essentials, and entertainment devices. TULU utilizes IoT-based smart rental units that are tailored to meet the needs of users, leveraging data to analyze behavior, optimize usage, and refine inventory. This approach enables TULU to enhance the living experience for urban dwellers while promoting efficient space usage and reducing waste. The company operates in 15 cities across the United States and Europe and collaborates with major landlords and top brand manufacturers to ensure a diverse and quality offering for its customers.

Vivodyne is a biotechnology company that specializes in developing an advanced automated robotic system aimed at discovering innovative drugs and cellular therapies. The company has created a microfluidic bioengineering platform that focuses on single-cell 4D phenomics, allowing for a detailed exploration of biological complexities. Its technology enables the cultivation of highly realistic human tissue models for drug discovery, incorporating an integrated confocal microscope. This platform not only accelerates the drug development process but also allows researchers to formulate tunable mixtures of compounds and cell therapies. Through its unique approach, Vivodyne seeks to advance the understanding of human health and facilitate the creation of effective treatments for various diseases.

AetherTouch is a technology company specializing in acoustic wave technology aimed at enhancing interaction with electronic devices. The company develops a software development kit that enables new applications to be integrated directly into operating systems, allowing for innovative control mechanisms without the need for touch screens. AetherTouch's technology utilizes advanced signal processing algorithms to leverage the unique characteristics of acoustic signals, providing precise 2D tracking for devices such as smartphones, tablets, and computers. This approach not only improves user experience but also addresses concerns related to power consumption and privacy that are often associated with conventional camera-based systems. Additionally, AetherTouch supports scientists in commercializing their technological advancements, fostering innovation in the industry.

Novosteo Inc. is a biotechnology company based in West Lafayette, Indiana, founded in 2017. The firm specializes in developing and manufacturing innovative drugs aimed at healing bone fractures and addressing related conditions that significantly impact patients' morbidity, mortality, and quality of life. With scientific guidance from co-founders Stewart Low and Philip Low of Purdue University, Novosteo utilizes a proprietary chemistry approach to bone targeting, which allows for the delivery of anabolic agents directly to fracture surfaces. This unique method focuses on accelerating bone regeneration and improving healing outcomes, thereby mitigating the debilitating effects associated with bone injuries and enhancing patient mobility and productivity.

Provivi Inc. is a biotechnology company based in Santa Monica, California, focused on the development of biopesticides for agricultural, commercial, household, and public health pest management. Founded in 2013, the company leverages biocatalysis technology, originally developed at the California Institute of Technology, to create insect pheromones that protect food supplies without toxic residues. Provivi aims to provide effective and environmentally friendly crop protection solutions, fostering sustainable agricultural practices. Its innovative approach targets the synthesis of biopesticides through advanced processes, allowing for the efficient production of safe and affordable pest management products. The company distributes its offerings worldwide, seeking to transform pest control with its groundbreaking biological solutions.

Anycart is a meal discovery and grocery shopping platform that simplifies the cooking process for users by integrating meal planning with grocery shopping. The application allows users to search for meals they wish to prepare, provides relevant recipes, and adds the necessary ingredients to their preferred grocery delivery service. It further enhances the cooking experience by offering step-by-step video instructions for each recipe. Founded in 2019 during the Amazon Alexa Accelerator and now based in Palo Alto, California, Anycart aims to make meal planning accessible and affordable, helping users efficiently utilize their grocery purchases by suggesting additional recipes that can use leftover ingredients.

Foldax, Inc., established in 2013 and headquartered in Salt Lake City, Utah, specializes in the design and manufacture of synthetic heart valves. The company's primary product is the Tria biopolymer heart valve, which can be implanted percutaneously or surgically to treat aortic, mitral, or tricuspid valve disease. Foldax aims to provide non-thrombogenic valves at a significantly lower cost compared to existing artificial or tissue valves, reducing the need for lifelong anticoagulant drugs and their associated risks. The company operates in the manufacturing sector, focusing on life polymer technology to create durable and effective heart valve replacements.

Specter Aerospace specializes in the development of advanced hypersonic vehicles that enhance combustion processes across energy, aerospace, and national security sectors. By utilizing plasma technology, the company modifies combustion reactions through a proprietary fuel nozzle design. This innovative approach addresses complex combustion challenges, resulting in significant improvements in emissions, operational efficiency, safety, and fuel consumption. Specter Aerospace aims to enable its clients to maximize the performance of advanced engines while minimizing environmental impact.

Turbodega S.A.C. is a technology company based in Lima, Peru, that specializes in developing a mobile application platform aimed at modernizing the supply chains of small grocery stores, known as bodegas. Founded in 2018, the company utilizes advanced artificial intelligence to automate ordering processes, optimize inventory management, and provide real-time tracking of daily sales. By digitizing and integrating supply chains, Turbodega empowers small retailers to enhance their operational efficiency and competitiveness against larger retail chains. The platform facilitates a seamless transition to a digital ecosystem, enabling bodegas to streamline their operations and ultimately increase their revenue.

Actinia is a technology company focused on the development of advanced detector technology for hard radiation, including gamma rays and X-rays. The company's innovative perovskite-based materials are designed to provide enhanced X-ray sensitivity and improved gamma-ray energy resolution. This technology serves a diverse clientele in critical sectors such as nuclear energy, non-proliferation, and medical imaging, facilitating more effective detection and analysis of radiation. Actinia's solutions aim to address the growing need for reliable and efficient radiation detection in various applications.

PteroDynamics is a company dedicated to enhancing transportation through sustainable autonomous vertical takeoff and landing (VTOL) aircraft. Since its inception in 2017, the company has focused on developing innovative aircraft that reduce environmental impact while improving efficiency. Its patented Transwing design features wings that fold and unfold during flight, allowing the aircraft to transition seamlessly between rotor-wing and fixed-wing modes. This technology optimizes cargo-carrying capabilities for long-range missions, making PteroDynamics' aircraft suitable for government, military, and commercial applications. By prioritizing energy efficiency and stability, PteroDynamics aims to revolutionize air mobility and facilitate the movement of people and goods across various distances.

Pinpoint Therapeutics is a preclinical stage biotechnology company focused on developing innovative cancer treatments that target autophagy, a critical pathway associated with cell survival and resistance to therapy. The company is creating inhibitors that specifically target PPT1, a recently identified enzyme in the autophagy pathway that is significantly expressed in various cancer types. By inhibiting this enzyme, Pinpoint Therapeutics aims to provide treatment options that can be effective against a wide range of cancers, either as standalone therapies or in combination with existing treatments, thereby addressing the challenge of therapy resistance in cancer care.

GuRu Wireless, Inc. enables safe, effective and customizable transmission of power over-the-air using proprietary millimeter-wave (mmWave) integrated circuits, modules and proprietary Smart RF Lensing technology. A miniature-sized power transfer system delivers power at an unprecedented distance efficiently and with precision. GuRu's wireless solution can be used as a charging hub or a power source in many settings where access to an energy source is needed. It is easy to install, safe, and sophisticated enough to find and adjust for various power levels to sync with the needs of any device. Even during use, it continuously charges devices and as a safety measure, reroutes power as necessary. Founded in 2017 by a team of scientists and engineers from Caltech, GuRu aims to ensure access to power be as ubiquitous as WiFi.

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Fort Worth, Texas, with an additional office in Dublin, Ireland. The company focuses on developing innovative therapeutics that inhibit Glycogen Synthase Kinase-3β (GSK-3β), a key enzyme involved in various biological processes linked to cancer and neurodegenerative diseases. Actuate's research primarily targets high-impact cancers, including glioblastoma, ovarian, breast, and pancreatic cancers, as well as conditions such as Alzheimer’s disease, bipolar disorder, and type II diabetes. The company's lead compound, elraglusib, is designed to enter cancer cells and disrupt GSK-3β function, thereby impeding tumor survival and proliferation. Actuate Therapeutics aims to advance its promising drug candidates through clinical development, demonstrating significant anti-tumor activity in challenging cancer types.

MixComm Inc. is a fabless semiconductor company based in Chatham, New Jersey, specializing in wireless technology solutions for a range of applications. Founded in 2017, the company develops advanced semiconductors for communications in smartphones, laptops, Wi-Fi routers, smart TVs, game consoles, virtual-reality headsets, and radar systems used in vehicles and defense electronics. Utilizing RFSOI process technology, MixComm focuses on creating millimeter-wave products that enhance performance and integration for 5G infrastructure and satellite communication. The company provides application-specific chips designed to meet the needs of various electronic components, facilitating innovative advancements in wireless communications technology.

Provivi Inc. is a biotechnology company based in Santa Monica, California, focused on the development of biopesticides for agricultural, commercial, household, and public health pest management. Founded in 2013, the company leverages biocatalysis technology, originally developed at the California Institute of Technology, to create insect pheromones that protect food supplies without toxic residues. Provivi aims to provide effective and environmentally friendly crop protection solutions, fostering sustainable agricultural practices. Its innovative approach targets the synthesis of biopesticides through advanced processes, allowing for the efficient production of safe and affordable pest management products. The company distributes its offerings worldwide, seeking to transform pest control with its groundbreaking biological solutions.

Linnaeus Therapeutics, Inc. is a biotechnology company focused on the identification and development of small molecule agents for the treatment of cancer and skin pigmentation disorders. Established in 2015 and based in Haddonfield, New Jersey, the company is built on research from the Ridky lab at the University of Pennsylvania. Linnaeus Therapeutics aims to create molecular therapeutics that modulate cellular differentiation, thereby enabling medical professionals to effectively treat conditions related to oncogenic mutations and pigmentation disorders. Through its innovative approach, the company seeks to advance cancer treatment and address challenges in skin pigmentation management.

New Age Meats is a biotechnology company based in San Francisco, California, founded in 2017. The company specializes in producing cultivated meat through an innovative automated, data-driven platform that utilizes stem cell technology. By growing meat from animal cells instead of relying on traditional animal slaughter, New Age Meats aims to create healthier and more sustainable food options.

Kencko Foods, Inc., established in 2017, is a New York-based company that produces and sells organic fruit and vegetable products in the U.S., U.K., and Canada. It specializes in sachet-based drinks, available in ten, thirty, and sixty packs, designed to provide convenient, hassle-free access to fresh, organic produce. Kencko's mission is to reinvent fresh organic fruits and vegetables into convenient products, preserving their nutritional content and making them easily consumable anytime, anywhere.

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Fort Worth, Texas, with an additional office in Dublin, Ireland. The company focuses on developing innovative therapeutics that inhibit Glycogen Synthase Kinase-3β (GSK-3β), a key enzyme involved in various biological processes linked to cancer and neurodegenerative diseases. Actuate's research primarily targets high-impact cancers, including glioblastoma, ovarian, breast, and pancreatic cancers, as well as conditions such as Alzheimer’s disease, bipolar disorder, and type II diabetes. The company's lead compound, elraglusib, is designed to enter cancer cells and disrupt GSK-3β function, thereby impeding tumor survival and proliferation. Actuate Therapeutics aims to advance its promising drug candidates through clinical development, demonstrating significant anti-tumor activity in challenging cancer types.

Xidas is a technology company specializing in the design and manufacture of advanced micro-scale solutions for various markets, including industrial applications, life-tech, and the Internet of Things (IoT). Utilizing a unique, multi-patented miniaturization paradigm known as Amalga, Xidas integrates innovative manufacturing technologies, design methodologies, and diverse materials processing to create products that were previously unattainable. The company's offerings include semiconductors, sensors, micro-actuators, and 3D microstructures, all crafted using non-silicon manufacturing processes. Xidas focuses on delivering highly integrated smart modules and sensors tailored for deployment in a wide range of IoT scenarios, thereby providing industry-first technologies to its customers.

Transient Plasma Systems, Inc. is a developer and manufacturer of pulsed power systems designed for a range of research and commercial applications. Founded in 2009 and based in Torrance, California, the company specializes in nanosecond pulsed power technology, which utilizes ultra-fast, high-voltage electrical pulses to generate high peak power with minimal energy consumption. This innovative technology creates energetic electrons throughout a volume rather than at a single point, resulting in a novel ignition process that enhances combustion efficiency and extends spark plug life. Transient Plasma Systems' products are applicable across various sectors, including automotive, defense, aerospace, energy, medicine, and agriculture, aiming to drive technological advancements in these fields.

Stoicheia is a nanotechnology company accelerating materials discovery by defining and expanding the materials genome. Using its proprietary lithography technology, Stoicheia has developed a way to create Megalibraries of nanomaterials on a chip. The company's technology also can be used to combine elements in new ways — already creating structures comprising up to seven elements.

Siege Pharmaceuticals is a biopharmaceutical company focused on developing innovative cancer therapies that leverage a naturally occurring molecule to effectively starve cancer cells. The company creates synthetic variants of this molecule, which possess optimized drug-like properties and target various pathways essential for cancer cell growth. By inhibiting these pathways, Siege Pharmaceuticals aims to prevent the development of resistance in cancer cells, thus providing medical practitioners with tools to better control the progression of the disease. The company’s approach is designed to enhance treatment efficacy and improve patient outcomes in the fight against cancer.

NVasc is an early-stage ophthalmology company with a focus on treating blindness. It specializes in treating the leading causes of blindness through choroidal and retinal revascularization. The company has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels in the retina and choroid in mouse models of ischemic eye diseases. The company is planning to manufacture NVB001 which can be used in toxicokinetic studies and in early clinical trials in humans.

Linnaeus Therapeutics, Inc. is a biotechnology company focused on the identification and development of small molecule agents for the treatment of cancer and skin pigmentation disorders. Established in 2015 and based in Haddonfield, New Jersey, the company is built on research from the Ridky lab at the University of Pennsylvania. Linnaeus Therapeutics aims to create molecular therapeutics that modulate cellular differentiation, thereby enabling medical professionals to effectively treat conditions related to oncogenic mutations and pigmentation disorders. Through its innovative approach, the company seeks to advance cancer treatment and address challenges in skin pigmentation management.

LifeSprout is developing the next generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine. They offer revolutionary products for aesthetic and regenerative medicine. They have created a platform that looks and behaves like the body’s own tissues. The company is turning this into a suite of products for millions of patients each year with soft tissue losses from aging, cancer, and metabolic disease.

PolyCera, Inc. specializes in the development and manufacturing of advanced ultrafiltration membranes made from organic polymer materials. Founded in 2012 and based in Los Angeles, California, the company offers products such as the PolyCera hydro, a sub-20 nm membrane effective in removing bacteria, viruses, and protozoa, and the PolyCera titan, a sub-5 nm membrane known for its stability in challenging conditions including extreme pH, temperature, and fouling. These membranes feature a unique Spiral Monolith design that combines the advantages of polymeric, tubular, and ceramic membranes, resulting in high permeability and reduced operational costs. PolyCera membranes are oleophobic and hydrophilic, allowing for easy backwashing, which minimizes downtime and the need for cleaning chemicals. With a current installed capacity exceeding 55 million gallons per day, PolyCera membranes are utilized in various sectors, including clean energy, industrial wastewater management, and municipal water treatment. The company was acquired in 2020 by PSP.US, Inc., which continues to market its innovative filtration products under the PolyCera brand.

nFugue is building on the groundbreaking work developed at Caltech to open a new level of nano-architected materials that can be used for a wide variety of applications, from tiny medical implants to ultra-lightweight impact-resistant fabrics or textiles to ultra-lightweight aircraft components. The revolutionary process will reduce the size of the 3D printed structures by 5x while enabling a whole new set of unprecedented combinations of properties, for example, ultra-lightweight; thermally insulating; strong, stiff, and low-density; and impact-absorbing.

Tanvas, Inc. is a technology company based in Chicago that specializes in the development of Surface Haptics technology. Founded in 2011, Tanvas focuses on enhancing touchscreen interactions by creating electrostatic fields that enable variable friction on glass surfaces. This innovation allows users to experience tactile sensations that correspond to visual content, effectively bridging the gap between digital and physical interactions. Tanvas's flagship product, TanvasTouch, can be integrated into various touch-enabled applications, including automotive interfaces, retail displays, consumer electronics, and solutions for the visually impaired. By providing a richer, more immersive experience, Tanvas aims to redefine the way people interact with digital devices.

Keren Therapeutics is harnessing the biology of a naturally occurring peptide hormone to restore muscle function in the context of several musculoskeletal and muscle wasting diseases. Using the same biological insights, Keren is also developing a therapeutic to counteract cognitive decline associated with age-related neurodegenerative conditions.

DigitalGenius, Inc. is a San Francisco-based company that specializes in developing artificial intelligence software solutions for customer service operations. Founded in 2013, the company has created an AI-powered platform designed specifically to enhance customer service for eCommerce. By utilizing advanced technologies such as conversational AI, visual recognition, and generative models, DigitalGenius automates and optimizes customer interactions across various channels. The platform effectively analyzes incoming messages, predicts metadata, routes cases, and provides agents with response suggestions, ensuring efficient resolution of customer inquiries. This integration into existing systems allows businesses to scale their customer service operations, significantly improving the quality and efficiency of conversations across text-based communication channels like email, chat, social media, and mobile messaging, ultimately enabling companies to meet and exceed customer expectations.

Provivi Inc. is a biotechnology company based in Santa Monica, California, focused on the development of biopesticides for agricultural, commercial, household, and public health pest management. Founded in 2013, the company leverages biocatalysis technology, originally developed at the California Institute of Technology, to create insect pheromones that protect food supplies without toxic residues. Provivi aims to provide effective and environmentally friendly crop protection solutions, fostering sustainable agricultural practices. Its innovative approach targets the synthesis of biopesticides through advanced processes, allowing for the efficient production of safe and affordable pest management products. The company distributes its offerings worldwide, seeking to transform pest control with its groundbreaking biological solutions.

1200 Pharma is a biotechnology company focused on accelerating pre-clinical drug discovery and clinical approval processes. Utilizing innovative medicinal chemistry technology developed at Caltech alongside proprietary biomarker-driven assays from UCLA, the company aims to streamline the drug development timeline. By integrating UCLA's advanced drug screening tools with Caltech's cutting-edge chemistry research, 1200 Pharma identifies promising therapeutic targets that enhance the likelihood of clinical success. This platform enables researchers to create proprietary drugs with distinct and optimized profiles, ultimately advancing the field of drug development.

Symbiotix Biotherapies is a biotechnology company focused on developing a novel class of molecular therapeutics aimed at treating inflammatory bowel disease, multiple sclerosis, and other serious immune-mediated conditions. The company's therapeutics are based on molecules derived from the human microbiome, allowing for the creation of first-in-class oral agents. These innovative treatments are designed to empower patients to manage their health more effectively and improve their quality of life. By harnessing the therapeutic potential of the microbiome, Symbiotix Biotherapies seeks to address significant unmet medical needs in the field of immune-mediated diseases.

MixComm Inc. is a fabless semiconductor company based in Chatham, New Jersey, specializing in wireless technology solutions for a range of applications. Founded in 2017, the company develops advanced semiconductors for communications in smartphones, laptops, Wi-Fi routers, smart TVs, game consoles, virtual-reality headsets, and radar systems used in vehicles and defense electronics. Utilizing RFSOI process technology, MixComm focuses on creating millimeter-wave products that enhance performance and integration for 5G infrastructure and satellite communication. The company provides application-specific chips designed to meet the needs of various electronic components, facilitating innovative advancements in wireless communications technology.

Diabetic Retinopathy is the leading cause of vision loss in adults worldwide. Opera Therapeutics is developing treatments based on technology from Columbia University that harnesses a natural cellular mechanism to prevent the damage and cell death that are hallmarks of Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO) which account for the majority of vision loss amongst people with diabetes. Unlike currently available anti-angiogenesis therapies which are injected directly into the eye, carry the risk of thromboembolic side effects, and are frequently ineffective, Opera Therapeutics is developing a biologic with a unique mechanism of acting for topical administration as an eye-drop, and aims to bring enhanced relief to patients suffering from diabetic retinopathy without the requirement for regular interocular injections. Opera Therapeutics is additionally exploring the utility of their biologics for treating stroke-induced edema in the brain.

Sienza Energy is focused on developing a groundbreaking approach to the design and manufacture of high-density rechargeable batteries. The company's innovative technology utilizes a 3D nanotechnology electrode structure that leverages recent advancements across multiple fields, distinguishing its battery design from traditional methods. This unique approach allows Sienza Energy to significantly enhance both the energy and power densities of its batteries while simultaneously lowering overall production costs. As a result, Sienza's products are poised to offer improved performance for a variety of applications, ranging from smart devices to electric vehicles.

Repairogen Corp., established in 2012 and based in New York, specializes in the healthcare sector, specifically biotechnology. The company focuses on developing premium anti-aging skincare ingredients and products, built upon a platform technology originating from an Ivy League medical research institution. Repairogen's proprietary and scientifically proven technology aims to provide customers with healthier, younger-looking skin by significantly reducing DNA damage in skin cells after UV exposure. This not only enhances skin appearance but also helps medical professionals reduce the risk of skin cancer among their patients.

GuRu Wireless, Inc. enables safe, effective and customizable transmission of power over-the-air using proprietary millimeter-wave (mmWave) integrated circuits, modules and proprietary Smart RF Lensing technology. A miniature-sized power transfer system delivers power at an unprecedented distance efficiently and with precision. GuRu's wireless solution can be used as a charging hub or a power source in many settings where access to an energy source is needed. It is easy to install, safe, and sophisticated enough to find and adjust for various power levels to sync with the needs of any device. Even during use, it continuously charges devices and as a safety measure, reroutes power as necessary. Founded in 2017 by a team of scientists and engineers from Caltech, GuRu aims to ensure access to power be as ubiquitous as WiFi.

Transient Plasma Systems, Inc. is a developer and manufacturer of pulsed power systems designed for a range of research and commercial applications. Founded in 2009 and based in Torrance, California, the company specializes in nanosecond pulsed power technology, which utilizes ultra-fast, high-voltage electrical pulses to generate high peak power with minimal energy consumption. This innovative technology creates energetic electrons throughout a volume rather than at a single point, resulting in a novel ignition process that enhances combustion efficiency and extends spark plug life. Transient Plasma Systems' products are applicable across various sectors, including automotive, defense, aerospace, energy, medicine, and agriculture, aiming to drive technological advancements in these fields.

Chimera Bioengineering is a biotechnology company focused on developing innovative gene therapeutics aimed at reprogramming the immune system to combat cancer. The company specializes in chimeric antigen receptor T-cells (CARs), which are engineered immune cells designed to bypass the immune evasion mechanisms employed by tumors. While CAR therapies have demonstrated significant success in treating liquid tumors, challenges remain in addressing solid tumors, including limited efficacy and potential toxicities. To overcome these obstacles, Chimera Bioengineering utilizes drug-responsive gene regulators to optimize CAR functionality. This approach enhances the ability of immune cells to target and eliminate tumor cells that express specific antigens, ultimately aiming to improve patient outcomes and reduce adverse effects. Through these advancements, Chimera Bioengineering aspires to offer effective solutions for patients who have not responded to conventional cancer treatments.

DEARHealth is a health technology company based in Beverly Hills, California, founded in 2013. It specializes in developing a Software as a Service (SaaS) based healthcare management platform tailored for medical providers and health insurers. The company leverages advanced data analytics to create disease-specific, coordinated care pathways that enhance provider workflows, support organizational decision-making, and engage patients through dedicated apps. DEARHealth's solutions are designed to improve health outcomes and experiences for chronically ill patients while reducing costs, with a focus on value-based healthcare.

NanoClear Technologies is a Los Angeles-based startup specializing in nanotechnology for surface modification. Founded by alumni from prestigious institutions like JPL/NASA, Caltech, UC Berkeley, UCLA, and MIT, the company holds proprietary technology capable of altering the wettability of any arbitrary surface. Their primary applications include anti-fogging solutions for consumer wearables and anti-frost performance in industrial settings, with potential use cases across automobile, aerospace, and solar panel industries.

Actinobac Biomed, Inc. is a biopharmaceutical company based in Kendall Park, New Jersey, founded in 2009. The company specializes in developing therapeutics for a range of medical conditions, including blood cancers, autoimmune and inflammatory diseases, and HIV. Its lead product, Leukotoxin, is a bacterial toxin that specifically targets and eliminates white blood cells, making it a promising candidate for treating hematologic malignancies such as leukemia and lymphoma. In addition to its primary focus on blood cancers, Actinobac Biomed is exploring the use of Leukotoxin and its derivatives for treating infectious diseases like HIV/AIDS and tuberculosis, as well as various autoimmune disorders, including rheumatoid arthritis and psoriasis. The company is committed to advancing its drug candidates through a strategic approach that prioritizes hematologic malignancies while also fostering early-stage drug discovery programs to maintain a robust pipeline of novel therapeutic agents.

3D Bio Holdings is a biotechnology company specializing in bioprinting technologies to create patient-specific living tissues for surgical healing. Founded in 2014, the company is headquartered in Brooklyn, New York, with an additional office in New York City. Utilizing proprietary technologies such as GMPrint and ColVivo, 3D Bio Holdings aims to address the limitations of the body's natural healing processes by providing therapeutic solutions for various diseases and congenital medical conditions.

Holoclara is an immunotherapy company focused on providing innovative solutions for individuals suffering from autoimmune disorders. The company specializes in delivering nematode-derived molecules known for their therapeutic properties. By identifying and developing these molecules from various worm species, Holoclara aims to create safe, orally available therapeutics that can improve the quality of life for patients. Through its targeted approach, Holoclara seeks to bring relief and promote overall health and well-being for those affected by autoimmune conditions.

Neuro-Bio is a start-up company dedicated to creating innovative therapeutics for neurodegenerative disorders, including Alzheimer's, Parkinson's, and Motor Neuron Disease. The company distinguishes itself through its pioneering approach to identifying the initial triggers of neurodegeneration, a concept developed by Baroness Professor Susan Greenfield over her 40-year career in neuroscience. Neuro-Bio focuses on the discovery and development of oral medications and biomarkers that identify novel amino acid bioactive peptides, offering physicians a more effective strategy for treating these debilitating conditions. Through its research and development efforts, Neuro-Bio aims to address the critical need for effective therapies in the field of neurodegeneration.

Amorphology is a manufacturer specializing in the production of lightweight metallic parts, utilizing advanced metal alloy technologies and innovative production techniques. The company focuses on creating specialty gears tailored for non-commercial robotics applications, particularly precision gearboxes designed for collaborative robots. By enhancing the performance, durability, elasticity, and wear resistance of these components, Amorphology aims to contribute to the advancement of robotic systems across various industries. Through its commitment to material innovation, the company seeks to deliver high-quality solutions that meet the evolving demands of the robotics sector.

Behavioral Signals is a technology company that specializes in analyzing human behavior through voice data. Its flagship product, AI-MC, leverages artificial intelligence to enhance customer service operations by automatically matching customers with the most suitable agents based on voice data and emotional analysis. The company employs proprietary technologies to recognize and interpret core emotions, moods, and behavioral patterns, translating these insights into key performance indicators for businesses. This capability allows clients to process data in real-time, gaining valuable emotional and demographic insights that can inform marketing strategies and improve overall call center performance. By focusing on emotion recognition and behavioral analytics, Behavioral Signals aims to help enterprises achieve greater profitability and optimize customer interactions.

Axial Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. Utilizing a microbiome discovery platform, the company targets the gut-brain axis to create innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Founded in 2013 and headquartered in Waltham, Massachusetts, Axial Biotherapeutics is in the clinical stage of its development, working to advance its pipeline of novel CNS therapeutics.

Axial Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. Utilizing a microbiome discovery platform, the company targets the gut-brain axis to create innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Founded in 2013 and headquartered in Waltham, Massachusetts, Axial Biotherapeutics is in the clinical stage of its development, working to advance its pipeline of novel CNS therapeutics.

Gene Sciences, Inc. is a biotechnology company based in San Diego, California, incorporated in 2016. The company focuses on the development of innovative DNA-targeted therapeutics aimed at modulating gene expression for the treatment of various human diseases. Gene Sciences serves customers primarily in the United States and is dedicated to advancing solutions that address unmet medical needs through its proprietary therapeutic approaches.

MemiRay, LLC is a health technology company based in Arcadia, California, founded in 2016. The company specializes in developing personal health monitoring devices, notably the InstaPath, which measures multiple human fluid analytics simultaneously. This device targets critical health concerns such as Diabetes Mellitus and Coronary Heart Disease while also monitoring personal hydration levels. MemiRay's innovative approach focuses on convenience and ease of use, facilitating improved regimen adherence and overall health management. Additionally, the company offers cloud-based informatics software designed to ensure data integrity, security, and precise time stamping for health-related data. MemiRay serves a diverse clientele, including individuals and various healthcare entities such as hospitals, health care centers, and pathology facilities, aiming to simplify health monitoring and enhance therapeutic outcomes.

KMLabs is a manufacturer of advanced laser systems tailored for research and industrial applications. The company specializes in ultrashort-pulse and short-wavelength laser technologies, providing optimized tabletop ultrafast laser sources that span the vacuum ultraviolet to soft X-ray range, specifically from 1 to 200 nanometers. Its laser systems find applications in various fields, including life sciences, material science, semiconductors, and manufacturing. KMLabs is dedicated to enhancing the capabilities of its products, offering flexible fiber lasers with high average power to meet the diverse needs of its customers.

Applaud Medical, Inc. is a medical device company based in San Francisco, California, focused on developing and commercializing innovative treatments for kidney stones, a condition affecting over 2 million individuals annually in the United States. Established in 2014, the company aims to address the limitations of existing treatments, which often require anesthesia and are only partially effective. Applaud Medical's novel approach will enable urologists to treat kidney stones measuring between 5 to 15 millimeters through a simple outpatient procedure, significantly improving patient outcomes and convenience.

Compellon, Inc. is a data analytics software company based in Laguna Hills, California, founded in 2010. It specializes in providing prescriptive analytics solutions to industries such as healthcare, financial services, and advertising. Compellon's product offerings include Iris Pro, an analytics advisory tool; Compellon 20|20, a clear-box analytics platform; and 20|20 Survey, a survey analytics solution. The company's innovative approach leverages advanced information theory and artificial intelligence to deliver actionable insights rapidly, allowing organizations to optimize outcomes efficiently. Compellon’s technology empowers business analysts by eliminating the need for extensive technical expertise, enabling them to make intelligent, data-driven decisions in real time. By focusing on complete business problems and providing strategic and tactical prescriptive actions, Compellon enhances the ability of organizations to respond effectively to dynamic competitive environments and complex data challenges.

Delpor, Inc. is a biotechnology company based in San Francisco, California, focused on the development of innovative drug delivery technologies. Founded in 2009, Delpor specializes in creating small, non-mechanical subcutaneous implant devices that enable sustained or pattern-specific release of proteins, peptides, and small molecules. Its key technologies include Prozor, designed for the delivery of antipsychotics and other small molecule drugs, and NANOPOR, which utilizes specialized membrane architecture for sustained release. Additionally, the company offers the Delos PUMP, an electro-osmotically driven system that allows for the precise delivery of drugs in programmed patterns, beneficial for conditions requiring periodic dosing such as hormone therapies and pain management. Delpor's technologies aim to enhance medication adherence and patient convenience by minimizing the need for frequent injections through simple in-office implantation procedures.

Provivi Inc. is a biotechnology company based in Santa Monica, California, focused on the development of biopesticides for agricultural, commercial, household, and public health pest management. Founded in 2013, the company leverages biocatalysis technology, originally developed at the California Institute of Technology, to create insect pheromones that protect food supplies without toxic residues. Provivi aims to provide effective and environmentally friendly crop protection solutions, fostering sustainable agricultural practices. Its innovative approach targets the synthesis of biopesticides through advanced processes, allowing for the efficient production of safe and affordable pest management products. The company distributes its offerings worldwide, seeking to transform pest control with its groundbreaking biological solutions.

Vivodyne is a biotechnology company that specializes in developing an advanced automated robotic system aimed at discovering innovative drugs and cellular therapies. The company has created a microfluidic bioengineering platform that focuses on single-cell 4D phenomics, allowing for a detailed exploration of biological complexities. Its technology enables the cultivation of highly realistic human tissue models for drug discovery, incorporating an integrated confocal microscope. This platform not only accelerates the drug development process but also allows researchers to formulate tunable mixtures of compounds and cell therapies. Through its unique approach, Vivodyne seeks to advance the understanding of human health and facilitate the creation of effective treatments for various diseases.